Shanghai Pioneer Holding Ltd

SEHK:1345 Voorraadrapport

Marktkapitalisatie: HK$2.3b

Shanghai Pioneer Holding Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Steven Yang

Algemeen directeur

CN¥655.0k

Totale compensatie

Percentage CEO-salaris78.8%
Dienstverband CEO1.6yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn4.5yrs
Gemiddelde ambtstermijn bestuur2.9yrs

Recente managementupdates

Recent updates

Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price

Jul 15
Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price

Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024

Apr 24
Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024

Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024

Apr 03
Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024

Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 01
Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings

Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks

Mar 22
Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks

Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital

Feb 26
Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital

Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?

Oct 21
Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?

Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024

Sep 18
Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024

Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024

Sep 01
Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024

Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching

Aug 09
Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching

Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Apr 14
Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 31
Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly

Dec 15
Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly

China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018

Sep 21
China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018

China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Sep 02
China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward

Jun 22
China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward

China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064

Apr 14
China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064

China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around

Jan 16
China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around

These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely

Oct 11
These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely

China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year

Sep 15
China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year

China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056

Sep 01
China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056

China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns

Aug 26
China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns

Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture

May 22
Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture

We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt

Apr 25
We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt

Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?

Mar 14
Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?

How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?

Feb 21
How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?

Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?

Feb 03
Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?

Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?

Jan 16
Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?

China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet

Dec 29
China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet

Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?

Dec 14
Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?

China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment

Nov 29
China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment

Analyse CEO-vergoeding

Hoe is Steven Yang's beloning veranderd ten opzichte van Shanghai Pioneer Holding's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

CN¥164m

Mar 31 2024n/an/a

CN¥155m

Dec 31 2023CN¥655kCN¥516k

CN¥146m

Sep 30 2023n/an/a

CN¥168m

Jun 30 2023n/an/a

CN¥190m

Mar 31 2023n/an/a

CN¥213m

Dec 31 2022CN¥752kCN¥624k

CN¥235m

Compensatie versus markt: De totale vergoeding ($USD 91.98K ) Steven } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 359.95K ).

Compensatie versus inkomsten: De vergoeding van Steven is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Steven Yang (36 yo)

1.6yrs

Tenure

CN¥655,000

Compensatie

Mr. Yuewen Yang, also known as Steven, serves as Chief Executive Officer since April 2023 and serves as its Executive Director since September 16, 2022 and served as Chief Operating Officer at Shanghai Pio...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Zhang Xinzhou Li
Executive Chairman11.8yrsCN¥2.05m0.95%
HK$ 22.2m
Yuewen Yang
CEO & Executive Director1.6yrsCN¥655.00kgeen gegevens
Quan Zhang
General Manager of Dental Business Division & Executive Director3.3yrsCN¥717.00kgeen gegevens
Yi Xue
Chief Financial Officer7.9yrsgeen gegevensgeen gegevens
Yong Zheng
General Manager of Investment Unitno datageen gegevensgeen gegevens
Jie Wang
Director of Personnelno datageen gegevensgeen gegevens
Ka Man Ng
Company Secretary5.7yrsgeen gegevensgeen gegevens

4.5yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1345 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Zhang Xinzhou Li
Executive Chairman11.8yrsCN¥2.05m0.95%
HK$ 22.2m
Yuewen Yang
CEO & Executive Director2.2yrsCN¥655.00kgeen gegevens
Quan Zhang
General Manager of Dental Business Division & Executive Director1.1yrsCN¥717.00kgeen gegevens
Chanshu Lai
Independent Non-Executive Director2.9yrsCN¥270.00kgeen gegevens
Hong Zhang
Independent Non-Executive Director5.8yrsgeen gegevensgeen gegevens
Mingfei Hu
Non-Executive Director3.9yrsCN¥184.00kgeen gegevens
Changhai Zhang
Independent Non-Executive Directorless than a yeargeen gegevensgeen gegevens

2.9yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1345 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.